Bid can mediate a pro-apoptotic response to etoposide and ionizing radiation without cleavage in its unstructured loop and in the absence of p53

Oncogene

Volumn 30, Issue 33, 2011, Pages 3636-3647

  Maas, C ^a   De Vries, E ^a   Tait, S W G ^a,b   Borst, J ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

apoptosis; Bid; DNA damage; p53

Indexed keywords

BH3 PROTEIN; CASPASE 9; DOUBLE STRANDED DNA; E1A PROTEIN; ETOPOSIDE; PROTEIN BAK; PROTEIN BAX; PROTEIN BID; PROTEIN P53; RAS PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PERMEABILIZATION; CELL TRANSFORMATION; CLONOGENESIS; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVATION; FIBROBLAST CULTURE; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SIMIAN VIRUS 40; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CELLS, CULTURED; DNA DAMAGE; ETOPOSIDE; MICE; MITOCHONDRIA; PROTEIN STRUCTURE, TERTIARY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80051798026     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.75     Document Type: Article

References (42)

1. Anguissola S, Koehler B, O'Byrne R, Duessmann H, Cannon MD, Murray FE et al. (2009). Bid and calpains cooperate to trigger oxaliplatin-induced apoptosis of cervical carcinoma HeLa cells. Mol Pharmacol 76: 998-1010.
2. Brown JM, Wouters BG. (1999). Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59: 1391-1399. (Pubitemid 29160097)
3. Chipuk JE, Green DR. (2006). Dissecting p53-dependent apoptosis. Cell Death Differ 13: 994-1002.
4. Chou JJ, Li H, Salvesen GS, Yuan J, Wagner G. (1999). Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell 96: 615-624. (Pubitemid 29122804)
5. Cirman T, Oresic K, Mazovec GD, Turk V, Reed JC, Myers RM et al. (2004). Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J Biol Chem 279: 3578-3587. (Pubitemid 38140598)
6. Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L et al. (2005). BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation-and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 106: 4131-4138. (Pubitemid 41775918)
7. Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C et al. (1999). Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 274: 1156-1163.
8. Gross A. (2006). BID as a double agent in cell life and death. Cell Cycle 5: 582-584.
9. Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES. (2002). Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 277: 13430-13437. (Pubitemid 34967937)
10. Kamer I, Sarig R, Zaltsman Y, Niv H, Oberkovitz G, Regev L et al. (2005). Proapoptotic BID is an ATM effector in the DNA-damage response. Cell 122: 593-603. (Pubitemid 41191157)
11. Kaufmann T, Tai L, Ekert PG, Huang DC, Norris F, Lindemann RK et al. (2007). The BH3-only protein bid is dispensable for DNA damage-and replicative stress-induced apoptosis or cell-cycle arrest. Cell 129: 423-433. (Pubitemid 46574974)
12. Koehler B, Anguissola S, Concannon CG, Rehm M, Kogel D, Prehn JH. (2008). Bid participates in genotoxic drug-induced apoptosis of HeLa cells and is essential for death receptor ligands' apoptotic and synergistic effects. PLoS One 3: e2844.
13. Krajewska M, Zapata JM, Meinhold-Heerlein I, Hedayat H, Monks A, Bettendorf H et al. (2002). Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia 4: 129-140. (Pubitemid 34218681)
14. Lam M, Dubyak G, Chen L, Nunez G, Miesfeld RL, Distelhorst CW. (1994). Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. Proc Natl Acad Sci USA 91: 6569-6573.
15. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2: 183-192. (Pubitemid 41043974)
16. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490. (Pubitemid 28391864)
17. Mandic A, Viktorsson K, Strandberg L, Heiden T, Hansson J, Linder S et al. (2002). Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. Mol Cell Biol 22: 3003-3013. (Pubitemid 34437459)
18. McDonnell JM, Fushman D, Milliman CL, Korsmeyer SJ, Cowburn D. (1999). Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists. Cell 96: 625-634. (Pubitemid 29122805)
19. Michalak EM, Villunger A, Adams JM, Strasser A. (2008). In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ 15: 1019-1029. (Pubitemid 351712606)
20. Oberkovitz G, Regev L, Gross A. (2007). Nucleocytoplasmic shuttling of BID is involved in regulating its activities in the DNA-damage response. Cell Death Differ 14: 1628-1634. (Pubitemid 47278848)
21. Ploner C, Kofler R, Villunger A. (2008). Noxa: at the tip of the balance between life and death. Oncogene 27(Suppl 1): S84-S92.
22. Ren D, Tu H-C, Kim H, Wang GX, Bean GR, Takeuchi O et al. (2010). BID, BIM, and PUMA are essential for activation of the BAX-and BAK-dependent cell death program. Science 330: 1390-1393.
23. Sarig R, Zaltsman Y, Marcellus RC, Flavell R, Mak TW, Gross A. (2003). BID-D59A is a potent inducer of apoptosis in primary embryonic fibroblasts. J Biol Chem 278: 10707-10715. (Pubitemid 36800341)
24. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El Deiry WS. (2002). BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 4: 842-849. (Pubitemid 35331358)
25. Schmitt CA, Rosenthal CT, Lowe SW. (2000). Genetic analysis of chemo-resistance in primary murine lymphomas. Nat Med 6: 1029-1035.
26. Shelton SN, Shawgo ME, Robertson JD. (2009). Cleavage of Bid by executioner caspases mediates feed forward amplification of mitochondrial outer membrane permeabilization during genotoxic stress-induced apoptosis in Jurkat cells. J Biol Chem 284: 11247-11255.
27. Simmen T, Aslan JE, Blagoveshchenskaya AD, Thomas L, Wan L, Xiang Y et al. (2005). PACS-2 controls endoplasmic reticulum-mitochondria communication and Bid-mediated apoptosis. EMBO J 24: 717-729. (Pubitemid 40396102)
28. Slee EA, Keogh SA, Martin SJ. (2000). Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ 7: 556-565. (Pubitemid 30303611)
29. Strasser A, Harris AW, Jacks T, Cory S. (1994). DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79: 329-339.
30. Tait SW, de Vries E, Maas C, Keller AM, D'Santos CS, Borst J. (2007). Apoptosis induction by Bid requires unconventional ubiquitination and degradation of its N-terminal fragment. J Cell Biol 179: 1453-1466.
31. Tan KO, Tan KM, Yu VC (1999). A novel BH3-like domain in BID is required for intramolecular interaction and autoinhibition of pro-apoptotic activity. J Biol Chem 274: 23687-23690.
32. Valentijn AJ, Gilmore AP. (2004). Translocation of full-length Bid to mitochondria during anoikis. J Biol Chem 279: 32848-32857. (Pubitemid 39014745)
33. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ et al. (2003). p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302: 1036-1038. (Pubitemid 37386194)
34. Wang X. (2001). The expanding role of mitochondria in apoptosis. Genes Dev 15: 2922-2933. (Pubitemid 33078942)
35. Ward MW, Rehm M, Duessmann H, Kacmar S, Concannon CG, Prehn JH. (2006). Real time single cell analysis of Bid cleavage and Bid translocation during caspase-dependent and neuronal caspase-independent apoptosis. J Biol Chem 281: 5837-5844. (Pubitemid 43847683)
36. Werner AB, Tait SW, de Vries E, Eldering E, Borst J. (2004). Requirement for aspartate-cleaved bid in apoptosis signaling by DNA-damaging anti-cancer regimens. J Biol Chem 279: 28771-28780. (Pubitemid 38900162)
37. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. (2007). Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859.
38. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. (2001). PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7: 673-682. (Pubitemid 32706358)
39. Zha J, Weiler S, Oh KJ, Wei MC, Korsmeyer SJ. (2000). Post-translational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. Science 290: 1761-1765. (Pubitemid 32004806)
40. Zinkel SS, Hurov KE, Gross A. (2007). Bid plays a role in the DNA damage response. Cell 130: 9-10. (Pubitemid 47031328)
41. Zinkel SS, Hurov KE, Ong C, Abtahi FM, Gross A, Korsmeyer SJ. (2005). A role for proapoptotic BID in the DNA-damage response. Cell 122: 579-591. (Pubitemid 41191156)
42. Zinkel SS, Ong CC, Ferguson DO, Iwasaki H, Akashi K, Bronson RT et al. (2003). Proapoptotic BID is required for myeloid homeostasis and tumor suppression. Genes Dev 17: 229-239. (Pubitemid 36105895)